Navigation Links
Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent

Moffitt Research Presented at 9th International Symposium on Myelodysplastic Syndromes

TAMPA, Fla., May 17, 2007 /PRNewswire/ -- New updated results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood cancer known as myelodysplastic syndromes (MDS) were presented today by Dr. Alan List, from the H. Lee Moffitt Cancer Center & Research Institute, at the 9th International Symposium on MDS currently taking place in Florence, Italy. Breakthrough data presented at the meeting showed that Revlimid, or lenalidomide, can provide long-term survival benefit and prevent disease progression in MDS patients with chromosome 5q deletion.

"These landmark data demonstrate that Revlimid, in many cases, can help patients with MDS live transfusion free for several years. More importantly, we found that Revlimid can provide a significant long-term survival advantage, with 87 percent of cytogenic responders having a ten-year survival estimate," said Dr. List, Professor of Oncology and Medicine and Chief, Division of Malignant Hematology at Moffitt, and lead investigator of the study. "It is very rewarding to see patients treated with Revlimid, living longer, living three or four years transfusion free and having a better quality of life overall."

The updated data presented by Dr. List at this year's Symposium showed that patients with MDS with chromosome 5q deletion who received Revlimid were able to remain transfusion free for an average of 2.2 years and, after four years, patients were still responding to treatment. Additionally, among patients who showed a cytogenic response to Revlimid, 87 percent had a ten year survival estimate compared to only four percent of non-cytogenic responders.

Additional data from a retrospective analysis of a German database on MDS patients treated with Revlimid was also presented at the Symposium and showed that Revlimid can also prevent dis
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:10/6/2008)... revealed that drinking polyphenol-rich 100% Conco...appetite, energy intake or body,weight, CONCORD, ...of 100%,polyphenol-rich Concord grape juice did no...d with changes in appetite and was shown to reduce...ed at the 49th Annual Meeting of,the American Coll...
(Date:10/3/2008)...to Study B-Raf Kinase Inhibitors for Cancer Treatm... 3 /-,Eli Lilly and Company...ceuticals, LLC today announced that the two compan...e licensing agreement related to,Deciphera,s precl...y of,potential oncology therapeutics., The collab...
(Date:10/2/2008)...eden, October 2 /- Calabar AB announc...n xerostomia ("dry mouth"),patients has been initi...,dry mouth patients between the ages of 20 to 75. ... evaluation in a succeeding Phase III efficacy,stu...terase inhibitor,physostigmine. It is administered...
(Date:10/1/2008)... therapeutic potential of Amylin,s integrated neur...rmacotherapy, SAN DIEGO, Oct. 1 /PRNewswire-First...LN ) today announced that new data for its pipelin... Annual Scientific Meeting of The,Obesity Society ...al,meeting is one of the largest and most comprehe...
Breaking Medicine Technology:Concord Grape Juice Has No Significant Impact on Body Weight 2Concord Grape Juice Has No Significant Impact on Body Weight 3Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement 2Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement 3Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 4Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 6Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 7California Nurses Association Courage Campaign Arianna Huffington Team up for Yacht Party 2 TV Ad 19224 1California Nurses Association Courage Campaign Arianna Huffington Team up for Yacht Party 2 TV Ad 19224 2California Nurses Association Courage Campaign Arianna Huffington Team up for Yacht Party 2 TV Ad 19224 3NJIT Provost Priscilla P Nelson honored at National Academy of Engineering 3295 1NJIT Provost Priscilla P Nelson honored at National Academy of Engineering 3295 2Sugar linkage could lead to better treatment for autoimmune diseases 3293 1Sugar linkage could lead to better treatment for autoimmune diseases 3293 2Therapy Yields Promise for Fatal Neurological Condition 19223 1Therapy Yields Promise for Fatal Neurological Condition 19223 2
... WIRE)--Jul 10, 2007 - Corgenix Medical,Corporatio...orators,reported new clinical data demonstrating a...he Company,s patented AtherOx(TM),bio-markers and ...the XXIst Congress of the International Society on...erland., Data released this week shows the associa...
... rHuPH20 with Humira Estimated to Increase the,Max...m 64% to 100%,-, SAN DIEGO, July 09, 2007 /PRNewsw...biopharmaceutical company developing and,commercia...that,final results of the Enhanze(TM) Technology c...d bioavailability of a,representative commercially...
Other Medicine Technology:Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 2Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 3Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 2Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 3Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 5
(Date:10/6/2008)...t. 6 /PRNewswire/ -- Developed in collaboration wi...ades, CA is introducing,Revolutionary Breast Surfa...c Surgery office of Dr. Steve Laverson this week i...he first of its kind, and is based on,breakthrough...with,innovative proprietary software. The XS-300(T...
(Date:10/6/2008)...ct. 6 /PRNewswire/ -- The organizers of Informex a...e on Global Sourcing for the,Pharmaceutical Indust...inceton Marriott in New Jersey USA., The conferen... the,Global Sourcing Council, and boasts an unpara...e likes of Johnson & Johnson, Bristol Myers Squibb...
(Date:10/6/2008)... LegalView recently posted detailed inform...he potentially serious side effects caused by the ... the drug,s potential side effects are the develop... for young adult and child patients. , ...- LegalView, the number one resource for everythin...
(Date:10/6/2008)... Hospital Ship Serving in West Africa Rece...Garden Valley, Texas October 6, 2008 -- www.seamob...l provider of communications services to remote lo...s to the FoxNews channel via satellite to Mercy Sh...ica Mercy. The Africa Mercy is the world,s larges...
Breaking Medicine News(10 mins):Health News:Plan Your Breasts in 3-D 2Health News:Global Sourcing Strategies for the Pharmaceutical Industry 10th - 11th November, Marriott Princeton, New Jersey USA 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3
...ivering drugs has long challenged scientists to de...drugs intact// until reaching their targets. Now...te for Lasers, Photonics and Biophotonics and Rosw...ed an innovative solution in which the delivery sy...
...ntists and dental hygienists as lifesavers, but Dr...assistant professor of dental// hygiene at New Yor...ssion to routinely conduct periodontal evaluations...ings as well as how to recognize the clinical sign...
...ind why cancer patients undergoing chemotherapy an...ss of appetite. //The study is also trying to inve...ients maintain a healthy diet during treatment. R...a studying the effects of chemotherapy and radiati...
...ignificant impact on quality of life. It is preval...0, and affects over //4.8 million people in the Un...identified, the cause of DES is still largely unkn...ency in the quantity and/or quality of tears, an u...
Other Medicine News:Health News:No Carrier Necessary: This Drug Delivers Itself 2Health News:No Carrier Necessary: This Drug Delivers Itself 3Health News:Medical Personnel Can Save More Lives by Screening for Oral Signs of Disease 2Health News:Medical Personnel Can Save More Lives by Screening for Oral Signs of Disease 3Health News:Medical Personnel Can Save More Lives by Screening for Oral Signs of Disease 4Health News:Special Diets Necessary for Those Undergoing Chemotherapy 2Health News:Dry Eye Syndrome Affects Visual Functions 2
...boratory and a worldwide leader in innovative labo...tensive test menu of highly complex and unique med...ed by the University of Utah, ARUP Laboratories' c...ersity teaching hospitals and children's hospitals...
...boratory and a worldwide leader in innovative labo...tensive test menu of highly complex and unique med...ed by the University of Utah, ARUP Laboratories' c...ersity teaching hospitals and children's hospitals...
...boratory and a worldwide leader in innovative labo...tensive test menu of highly complex and unique med...ed by the University of Utah, ARUP Laboratories' c...ersity teaching hospitals and children's hospitals...
...boratory and a worldwide leader in innovative labo...tensive test menu of highly complex and unique med...ed by the University of Utah, ARUP Laboratories' c...ersity teaching hospitals and children's hospitals...
Medicine Products: